secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001933414-24-000056
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Q3 net loss widens to $56.3M; pivotal trial enrollments complete, data due H1 2025
--------------------------------------------------------------------------------

- Net loss of $56.3M for Q3 2024 vs $22.8M in Q3 2023; R&D expense rose to $54.0M from $22.5M.
- Cash & investments $263.6M; company believes sufficient to fund operations into 2026.
- Advance-HTN pivotal trial fully enrolled; topline data expected March 2025.
- Launch-HTN Phase 3 trial enrolled ahead of schedule; topline data anticipated mid first half 2025.
- Explore-CKD Phase 2 trial enrollment ongoing; topline data expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/0001933414-24-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000056/mlys-20241111.htm
  HTML page:      https://secwatch.observer/filing/0001933414-24-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer